SAFETY WARNING: ABACAVIR USE IN HLA-B*5701 POSITIVE PATIENTS AND UNTESTED PATIENTS

By /

July, 2009 – The Pharmacovigilance Initiative at the BC Centre for Excellence in HIV/AIDS received a report of an HLA-B*5701 positive patient who had tolerated long term abacavir therapy, discontinued antiretroviral drugs for several months, then developed a diffuse rash, respiratory distress and fever shortly after re-initiating an abacavir-containing regimen. The symptoms and rapid onset were consistent with a clinical diagnosis of abacavir hypersensitivity reaction.

For more information: Click here to download the BC-CfE Safety Alert (PDF)

Scroll to Top

Canada Post has provided notification of restarting their operations on December 17, 2024. As Canada Post ramps up and stabilizes their services, the BC-CfE will continue the following measures on an interim basis to minimize service disruption to BC-CfE clients and providers.

  • The BC-CfE Laboratory will utilize private courier for delivery of outgoing reports and documents. (Lab Contact Information: Phone 604-806-8775; FAX 604-806-9463)
  • The BC-CfE Drug Treatment Program (DTP) will fax outgoing forms and documents to the provider’s office. (DTP Contact Information: Phone 604-806-8515; FAX 604-806-9044)
  • St. Paul’s Hospital Ambulatory Pharmacy will utilize private courier for delivery of medications. (Contact Information: Phone 1-800-547-3622; FAX 604-806-8675)

Start typing and press enter to search